Marketing authorization holders of authorized medicines for human/veterinary use are no longer obliged to inform both the Federal Agency for Medicines and Health Products (FAMHP) and the National Institute for Health and Disability Insurance (NIHDI) of any changes in commercialization of her medicinal products. As from 1 January 2014, the FAMHP is the central desk for reporting the commercialization as well as a temporary unavailability or a permanent cessation of commercialization of a medicinal product in Belgium. More information can be found on the FAMHP website: circular 605

Share This